Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Little to choose between catheter types for intermittent self-catheterization

Patients undertaking intermittent self catheterization for urinary retention should be offered the choice of clean noncoated, hydrophilic, or gel reservoir catheters, say researchers who found none offers a strong advantage in avoiding urinary tract infection.

14 Jan 2013

Primary-care clinic treatment improves patient follow up

Treating low-acuity emergency-department patients in a primary-care clinic results in better future primary care follow up, research shows.

14 Jan 2013

Repeated toxin treatment sustains benefits in incontinence patients

Repeated treatment with onabotulinumtoxinA consistently reduces urinary incontinence episodes in patients with neurogenic detrusor overactivity, show findings from an extension study of Phase III trials.

7 Jan 2013

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

3 Jan 2013

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Thulium vapoenucleation well-tolerated for treating benign prostate obstruction

Treating benign prostate obstruction with thulium vapoenucleation of the prostate is well-tolerated and effective and leads to a low incidence of perioperative complications, according to recent study findings.

10 Dec 2012

Antimicrobial catheters do not significantly reduce UTI risk

Silver alloy-coated antimicrobial catheters do not significantly reduce the risk for catheter-associated urinary tract infection compared with standard catheters in adult hospital patients requiring short-term catheterization, show UK study results.

10 Dec 2012

Administrative data quantify hospital infection risk

Administrative hospital data can successfully quantify the incidence of healthcare-associated urinary tract infection, indicating the data's potential use for risk monitoring and surveillance of this frequent occurrence, show systematic review results.

3 Dec 2012

Neurologist care lowers risk for PD-related hospitalizations

Regular care by a neurologist lowers the risk for hospitalization for Parkinson's disease-related complications, US research shows.

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Antibiotic choices critical for elderly with bloodstream infections

Failure to treat patients with bacteremia with an appropriate antibiotic is particularly harmful in elderly patients, report researchers.

8 Nov 2012

Canine lymphoma treatment adds up to cystitis

High cumulative doses of the alkylator cyclophosphamide could be to blame for the development of sterile hemorrhagic cystitis in dogs being treated for lymphoma, indicate the results of a US study.

8 Nov 2012

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

The American Urological Association (AUA) introduces new clinical guidelines for the treatment of Overactive Bladder, Urodynamics, Hematuria, and Vasectomy.

24 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

Women more likely to develop UTI after pelvic-floor surgery

Women who have a positive urine culture test on the day of surgery for a pelvic-floor disorder are more likely to have a urinary tract infection (UTI) in the first six weeks after the procedure.

9 Oct 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Research roundup: Reducing risk in shared savings programs

The Design And Application Of Shared Savings Programs: Lessons From Early Adopters --"Shared savings programs reward providers for holding spending below specific targets, thus introducing a level of financial accountability not present in strictly volume-based payment models, such as fee-for-service," researchers write.

7 Sep 2012